To test this hypothesis, we subcutaneously inoculated BALB/c mice with the control or Arf1‐ablated CT26 cells, and then administrated mice with anti‐IFNAR1 and anti‐IL‐1β antibodies or isotype control antibodies at day 0, 2, and 4 after tumor cell injection, respectively. The gene discussed is ARF1; the disease is neoplasm.